Allergan Receives FDA Approval for Migraine Treatment

January 9, 2020

Allergan Receives FDA Approval for Migraine Treatment

UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks. The therapy is taken by the user once a migraine starts — UBRELVY then provides relief for up to 24 hours. Yourway supports a patient-centric supply chain so that drugs in clinical trials can reach patients faster, regardless of where they are located.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

Schedule a Meeting

GCSG 2026 US Conference

April 26-29, 2026
San Diego, CA

Schedule a Meeting

Media

Articles

White-Glove by Design: The Yourway Standard in Clinical Logistics

Open chat

Hello! How can I help you?